Table 1 Clinical characteristics in patients with high vs. low LncRNA scores
From: Role of LncRNA score and PVT1 in primary hyperparathyroidism-- a preliminary study
Clinical characteristics | Patients with Low lncRNA score (n = 29) | Patients with High lncRNA score (n = 28) | P-value | |
|---|---|---|---|---|
Age (SD)(years) | 56.5 (14.5) | 60.1 (11.1) | 0.286 | |
Sex (% M) | 24.1 | 46.4 | 0.068 | |
Disease course (SD) (month) | 67.0 (97.5) | 74.0 (90.96) | 0.784 | |
Cause of first diagnosis (%) | With any discomfort | 51.7 | 75.0 | 0.100 |
discomfort in Bone system | 31.0 | 35.7 | 0.783 | |
Nephrolith | 17.2 | 14.3 | 0.100 | |
Discomfort in Digestive system | 3.5 | 10.7 | 0.352 | |
Thyroid nodular | 10.3 | 14.3 | 0.706 | |
Elevated Ca2+ level | 27.6 | 21.4 | 0.760 | |
Clinical manifestation (%) | Bone system | 72.4 | 60.7 | 0.408 |
Nephrolith | 55.2 | 25.0 | 0.031 | |
Digestive system | 24.1 | 32.1 | 0.565 | |
Laboratory examination | iPTH (SD) (pg/mL) | 604.6 (624.2) | 544.9 (592.3) | 0.713 |
Ca2+(SD) (mmol/L) | 2.75 (0.32) | 2.98 (0.42) | 0.028* | |
Albumin adjusted Ca2+(SD)(mmol/L) | 2.73 (0.32) | 2.98 (0.45) | 0.020* | |
P (SD)(mmol/L) | 0.79 (0.25) | 0.89 (0.49) | 0.363 | |
ALP (SD) (U/L) | 236.8 (359.0) | 121.9 (52.0) | 0.099 | |
Imaging location consistent with histopathology (%, n) | Tc-99 m-MIBI | 81.0 (n = 21) | 86.7 (n = 15) | 1.000 |
Contrast enhanced CT | 53.3 (n = 15) | 88.9 (n = 9) | 0.073 | |
Thyroid ultrasound | 75.0 (n = 24) | 66.7 (n = 8) | 0.440 | |
Histopathology | Maximum diameter (SD) (cm) | 2.10 (2.31) | 2.48 (1.31) | 0.271 |
parathyroid cancer (%, n) | 6.9 | 32.1 | 0.021# | |
lncRNA PVT1 (SD) | 0.32 (0.44) | 2.72 (4.89) | 0.015* | |